[{"id":"ef958c21-2bd2-4580-9476-499c60150559","acronym":"VICKI","url":"https://clinicaltrials.gov/study/NCT06020651","created_at":"2023-08-31T13:09:53.820Z","updated_at":"2024-07-02T16:35:38.540Z","phase":"","brief_title":"Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside","source_id_and_acronym":"NCT06020651 - VICKI","lead_sponsor":"Institut Mutualiste Montsouris","biomarkers":" VEGFA • IFNG • TNFA • CD31 • IL1B • PECAM1 • CDH5 • ITGA2B","pipe":"","alterations":" ","tags":["VEGFA • IFNG • TNFA • CD31 • IL1B • PECAM1 • CDH5 • ITGA2B"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-08-31"},{"id":"ccce9fc3-2973-480c-9d97-2280a89400ca","acronym":"VASCATAQ","url":"https://clinicaltrials.gov/study/NCT04813913","created_at":"2021-03-24T15:11:23.089Z","updated_at":"2024-07-02T16:36:32.925Z","phase":"Phase 4","brief_title":"VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer","source_id_and_acronym":"NCT04813913 - VASCATAQ","lead_sponsor":"University Hospital, Rouen","biomarkers":" KRAS • BRAF • NRAS • HIF1A • CDH5","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation","tags":["KRAS • BRAF • NRAS • HIF1A • CDH5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/05/2019","start_date":" 05/05/2019","primary_txt":" Primary completion: 11/05/2022","primary_completion_date":" 11/05/2022","study_txt":" Completion: 11/05/2022","study_completion_date":" 11/05/2022","last_update_posted":"2021-03-24"}]